8-K filed May 4, 2026, 7:59 PM ET ticker COAG CIK 0002114044

other material confidence high sentiment positive materiality 0.85

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

Hemab Therapeutics Holdings, Inc.

IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.
Gross proceeds of $346.7 million before underwriting discounts and estimated offering expenses.
Common stock begins trading on Nasdaq Global Select Market under ticker 'COAG'.
Restated certificate increases authorized common shares to 400M, establishes classified board with staggered three-year terms.
Stockholder written consent and special meeting rights eliminated; exclusive forum provisions adopted.

item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-203988
form_type: 8-K
ticker: COAG
cik: 0002114044
company_name: Hemab Therapeutics Holdings, Inc.
filed_at: 2026-05-04T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.502659+00:00
generated_at: 2026-05-15T00:07:04.192666+00:00
sec_items: ["5.03", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-203988
json_url: https://secwatch.observer/filing/0001193125-26-203988.json
markdown_url: https://secwatch.observer/filing/0001193125-26-203988.md
text_url: https://secwatch.observer/filing/0001193125-26-203988.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/d149100d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

2d7179390aa334615ded7018b98ca04048214493

Hemab Therapeutics Holdings, Inc.: Filed a restated certificate of incorporation that increases authorized common stock, eliminates preferred stock references, authorizes undesignated preferred stock, establishes a classified board, modifies director removal and vacancy procedures, eliminates stockholder action by written consent and (effective 2026-05-04).

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

9b8538782e0f1a67c65c74cbdd3ee86a381e67e4

Hemab Therapeutics Holdings, Inc.: Amended and restated bylaws to eliminate stockholder action by written consent, establish procedures for stockholder proposals and director nominations, and conform to the restated certificate (effective 2026-05-04).

On May 4, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), which were previously approved by the Company’s board of directors and stockholders, became effective upon the closing of the IPO.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

ADT

Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan

ADT Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.

Filing page SEC filing

QLEP

Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE

Quantum Leap Acquisition Corp May 6, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.

Filing page SEC filing

MCAH

Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30

Mountain Crest Acquisition 6 Corp. May 5, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.

Filing page SEC filing

RREV

RRE Ventures Acquisition Corp. prices and closes $250M IPO; units begin trading on Nasdaq

RRE Ventures Acquisition Corp. May 1, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

On April 28, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which was effective on April 29, 2026.

Filing page SEC filing

DMAA

SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M

Drugs Made In America Acquisition Corp. May 1, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month

Filing page SEC filing

BAFN

BayFirst raises $80M in PIPE, reports Q1 loss of $5.7M, names new bank CEO

BayFirst Financial Corp. April 30, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 2.02, 5.02, 7.01, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

On April 28, 2026, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Division of Corporations creating and authorizing 4,000 shares of Series D Preferred Stock and 4,000 shares of Series E Preferred Stock.

Filing page SEC filing

SUJA

Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026

SUJA LIFE, INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Comparable filing

On May 7, 2026, the Company filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-203988

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.